ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE - Seite 3

      ⁽¹⁾           Excluding €71.4 million net proceeds from the private placement of new shares (1 June 2016)
      ⁽²⁾           Excluding €97.2 million net proceeds from the convertible bond (20 May 2015)
      ⁽³⁾           Including €1.3 million in restricted cash
      ⁽⁴⁾           Including €1.6 million restricted cash
* Defined as liquidity position in the cash flow statement

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   [phone]
m: [phone]
e:  [e-mail]

Marieke Vermeersch
Director IR & Corporate Communications
t:   [phone]
m: [phone]
e:  [e-mail]
Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: [phone]
e: [e-mail]

pdf format of the press release

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire